A step closer to a robust applied biomarker for the diagnosis and prognosis of sepsis and septic shock.

Researchers working at EpiDisease SL, INCLIVA, CIBERER and the University of Valencia have carried out clinical research on the use of circulating histones as biomarkers that suggests a potential application for early diagnosis and prognosis of septic patients.

Their work indicates that circulating histone levels can be used distinguish between organ dysfunction and organ failure at a very early stage, permitting the use of a more aggressive strategy via earlier initiation of organ support, which in turn could help improve sepsis survival.

EpiDisease SL is currently working to translate these potentially disruptive findings into a CE certified IVD tool with the diagnostic and prognostic capabilities for sepsis and septic shock prediction.

This  game-changing  development will allow physicians to stratify suspicion-of-sepsis patients within 60 minutes of first contact via a minimally invasive blood sample, allowing evidence-based and personalised life-saving treatments to be applied early  to improve outcomes for a pathology that claims 11 million lives a year globally.